TXMD TherapeuticsMD, Inc.
Healthcare$2.11-0.47%ClosedMarket Cap: $24.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.91
P/S
7.32
EV/EBITDA
-5.64
DCF Value
$-17.86
FCF Yield
10.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.3%
Operating Margin
-111.7%
Net Margin
5.3%
ROE
0.7%
ROA
0.5%
ROIC
-8.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $724.0K | 55.1% | $-723.0K | $95.0K | $— | — |
| Q4 null | $893.0K | 100.0% | $-1.5M | $-619.0K | $— | — |
| FY null | $3.0M | 100.0% | $-4.2M | $-569.0K | $— | — |
| Q3 null | $784.0K | 100.0% | $-830.0K | $152.0K | $— | — |
| Q2 null | $952.0K | 100.0% | $-695.0K | $551.0K | $— | — |
| Q1 null | $393.0K | 100.0% | $-871.0K | $-653.0K | $— | — |
| Q4 null | $667.0K | 100.0% | $-319.0K | $252.0K | $— | — |
| FY null | $1.8M | 100.0% | $-4.8M | $-2.2M | $— | — |
| Q3 null | $547.0K | 100.0% | $-859.0K | $-609.0K | $— | — |
| Q2 null | $234.0K | 100.0% | $-2.8M | $-1.1M | $— | — |
| Q1 null | $313.0K | 100.0% | $-1.1M | $-734.0K | $— | — |
| Q4 2023 | $502.0K | -26.9% | $-1.6M | $-883.0K | $-0.08 | — |